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HDL cholesterolAbstract The importance of non-pharmacological control of plasma cholesterol
levels in the population is increasing, along with the number of subjects whose
plasma lipid levels are non-optimal, or frankly elevated, according to international
guidelines. In this context, a panel of experts, organized and coordinated by the
Nutrition Foundation of Italy, has evaluated the nutritional and lifestyle interven-
tions to be adopted in the control of plasma cholesterol levels (and specifically
of LDL cholesterol levels). This Consensus document summarizes the view of the
panel on this topic, with the aim to provide an updated support to clinicians and
other health professionals involved in cardiovascular prevention.
ª 2007 Elsevier B.V. All rights reserved.Several ecological and epidemiological studies
have proved that elevated plasma levels of total
and, in particular, low-density lipoprotein (LDL)
cholesterol are associated with an increased risk
of coronary and, in general, cardiovascular
events [1]. More recently, many controlled
studies undertaken with dietary or pharmacolog-
ical interventions have demonstrated that
reduced plasma levels of total and LDL choles-
terol (LDL-C) result in a decreased incidence of
such events. The risk reduction is strongly re-
lated to the magnitude of the decline in LDL-C.
In general, a 1% decrease in plasma levels of to-
tal or LDL-C is followed, on average, by a 1%
risk-reduction. Moreover, the effect on cardio-
vascular risk appears to be independent of the
methods used to achieve a lower plasma choles-
terol level [2].
The large majority of epidemiological studies
have also demonstrated that elevated plasma
triacylglycerol (triglyceride) and/or reduced
plasma high-density lipoprotein (HDL) cholesterol
concentrations are associated with increased car-
diovascular risk. However, the results of pharma-
cological intervention trials to modify these
parameters have been equivocal and there is no
consensus, from the preventive point of view, on
the appropriateness of this approach in the general
population.
Conversely, the various lifestyle and dietary
interventions that affect plasma HDL cholesterol
(HDL-C) and triglyceride levels are usually consid-
ered effective in cardiovascular risk reduction.
This probably results from:a. the low risk associated with dietary and life-
style interventions;
b. the fact that many of the interventions that re-
duce plasma triglyceride levels and increase
plasma HDL cholesterol levels have additional
favorable effects (e.g., on weight manage-
ment, systemic inflammation, and insulin sen-
sitivity), and, hence, are worth implementing
in the general population and in individuals.
Yet, it is necessary to establish clear priorities
among the different lipid-lowering interventions,
and to focus prevention on the reduction of total
and plasma LDL cholesterol levels. This is espe-
cially required because health-care providers
frequently misunderstand what the results of
epidemiological studies show, as opposed to those
of intervention trials.
With this in mind, the Nutrition Foundation of
Italy (NFI) organized and coordinated a panel of
experts who examined the information regarding
the nutritional and lifestyle control of cholester-
olemia. The goal is to provide clinicians and other
health professionals involved in cardiovascular
prevention with an up-to-date review of the avail-
able evidence.
This statement has been formulated according
to the following procedure:
a) agreement on the outline;
b) writing of individual chapters by selected panel
members and peer review of these by other
panel members;
c) summary of the outcomes;
Non-pharmacological control of plasma cholesterol 3d) revision by all of the panel members;
e) revision by an external expert.
This paper focuses on the effects on total and
plasma LDL cholesterol levels, along with those on
other lipid parameters, of interventions to:
a) modify the pattern of consumption of dietary
fatty acids;
b) reduce the dietary intake of cholesterol;
c) modify the pattern of consumption of carbohy-
drates and fiber;
d) change the proportional intake of other micro-
and macronutrients;
e) manage weight;
f) supplement with phytosterol-enriched foods or
soy protein;
g) take regular exercise.
These interventions will also be evaluated in
light of their incorporation into the average Med-
iterranean (Italian) diet. Specific conditions (e.g.,
the menopause) in which such interventions might
be detrimental (e.g., through an increase in the
risk of osteoporosis), are also discussed.Dietary fatty acids and cholesterolemia
Correlations between fatty acid intake and cho-
lesterolemia were described in the second half of
the twentieth century, when the Seven Countries
Study by Keys and colleagues demonstrated how
total plasma cholesterol levels increases together
with the proportion of fat in the diet. Several
subsequent studies that examined the effects of
individual fatty acids on both total plasma cho-
lesterol levels and the different lipoprotein sub-
classes, namely LDL and HDL, improved our
understanding of this correlation [3]. Several ep-
idemiological and interventional studies exam-
ined the effects of dietary fatty acids on
lipoprotein metabolism and cholesterol trans-
port. Overall, the available data suggest that,
when isocalorically substituted for nutrients
with neutral effects on cholesterolemia (such as
carbohydrates), saturated and trans fatty acids
tend to increase total and plasma LDL cholesterol
levels. Conversely, polyunsaturated, cis fatty
acids (namely, those of the n-6 series such as li-
noleic acid) induce the opposite effects. Mono-
unsaturates, such as oleic acid, also reduce total
and plasma LDL cholesterol levels, although to
a lesser extent than do n-6 polyunsaturates. The
effects of fatty acids on plasma HDL cholesterol
levels are [2]:a) an increase after saturates intake;
b) an increase (to a lesser degree) after monoun-
saturate consumption;
c) no change after polyunsaturates;
d) a decrease after trans ingestion.
In terms of fat content, it is important to base
food choices on up-to-date composition tables,
since changes in the fatty acid composition of
several food items (e.g., meat) as a consequence
of new diets for animals and new food-processing
techniques are sometimes relevant. As an exam-
ple, pork meat is nowadays lower in saturated and
total fats, but higher in mono- and polyunsatu-
rated fatty acids (PUFAs), as compared with
40 years ago.Saturated fatty acids
The substitution of a percentage of dietary carbo-
hydrates with an isocaloric portion of saturated
fatty acids (mostly found in red meat, sausage,
dairy products, such as butter and cheese, and
some tropical oils, such as coconut and palm)
increases total plasma cholesterol levels [2]. In
general, saturated fatty acids increase both total
and HDL-C levels; hence, they tend not to modify
significantly, or to only slightly worsen, their ratio.
On the other hand, preliminary data suggest that,
from a functional point of view, HDL associated
with an increased consumption of saturates might
be less active than native HDL, but the evidence
on this issue is still not conclusive [4].
In particular, the response of cholesterolemia
and its subfractions to fatty acids of different
chain lengths appears to be diverse. For example,
saturated fatty acids with eight to ten carbon
atoms (caprylic and capric acids) increase plasma
LDL cholesterol levels but do not affect HDL levels.
The greatest hypercholesterolemic effect is attrib-
uted to fatty acids with 12e16 carbon atoms.
However, as lauric, myristic, and palmitic acids
(12, 14, and 16 carbon atoms, respectively) are
concomitantly present in most food items, it is
difficult to ascertain their individual effects [5].
A recent meta-analysis that compared the
effects of these three fatty acids when they are
substituted isocalorically for carbohydrates indi-
cates that, as the number of carbon atoms in-
creases, the hypercholesterolemic effect on both
the LDL and HDL fractions tapers off. Lauric acid
appears to exert a more prominent effect on HDL
than on plasma LDL cholesterol levels; stearic
acid, quantitatively the second fatty acid of the
diet, reduces plasma LDL cholesterol levels, as
4 A. Poli et al.does oleic acid when substituted for lauric, myr-
istic, palmitic, or trans fatty acids [6]. It is inter-
esting that stearic acid can be converted into
oleate in vivo. The results of several observational
and intervention studies on the role of stearic acid
on plasma HDL cholesterol levels (which some-
times is reduced, but is often unchanged) are still
equivocal. Variations of plasma LDL cholesterol
levels are negligible when stearic acid is isocalori-
cally substituted for carbohydrates [7].
Most international guidelines suggest that to
improve cholesterol levels saturated fat intake
should be lower than 10% of the total caloric
intake [8]. Reasonably, the optimal intake of satu-
rated fatty acids could be 7e10% of total calories;
interestingly, in Italy the consumption of such
fatty acids is, on average, 10.4% of total calories
[Istituto Nazionale di Ricerca per gli Alimenti e la
Nutrizione (INRAN), unpublished data].Monounsaturated fatty acids
According to the majority of published studies,
oleic acid [mostly found in olive oil, in some
variants of sunflower and safflower oils (called
‘high oleic’) and in the Canadian rapeseed oil
version (canola), as well as in some animal prod-
ucts such as lard] does not significantly influence
total plasma cholesterol levels. This is also the
case for other monounsaturated fatty acids (MU-
FAs). Indeed, monounsaturate consumption is not
used in any of the equations to calculate the
changes in cholesterolemia associated with spe-
cific fatty acid intake, such as those proposed by
Hegsted et al. [9] and Keys [10]. This neutral effect
of oleate seems to result from a concomitant in-
crease of plasma HDL cholesterol levels and a mod-
est reduction of plasma LDL cholesterol levels,
which thus increases the HDL/LDL ratio, which is
inversely related to cardiovascular risk.
According to two studies performed by Grundy
et al. [11] and by Mensink et al. [6] in the late
1980s, a diet very rich in monounsaturates (24
and 28% of total calories, respectively) and poor
in saturates decreases plasma LDL cholesterol
levels to an extent similar to that obtained with
a low-fat, high-carbohydrate diet.
The global effect of monounsaturates on the
lipid profile might explain, at least in part, the
results of the epidemiological studies and of the
observations by Key (in the 1970s) that the Medi-
terranean diet, rich in mono-unsaturates, is asso-
ciated with decreased cardiovascular risk.
However, it is interesting that studies carried out
in North American countries (where the mainsource of mono-unsaturates is not olive oil but,
rather, other oils or animal products) often failed
to observe a protective effect of monounsatu-
rates. For example, in the Nurses’ Health Study
the correlation between monounsaturate intake
and cardiovascular morbidity was negligible at the
first follow-up and modest at the second [12].
This discrepancy might be explained if, in
addition to oleic acid, the minor components of
olive oil contribute to the protective effect ob-
served in the Mediterranean countries. However,
this issue has not been resolved as yet.
Based on the available data, the Adult Treat-
ment Panel III (ATP-III) in 2001 recommended the
proportion of mono-unsaturates be raised from
10% to 15% in the optimal diet for cholesterolemia
control [8]. Similar levels of monounsaturate con-
sumption are also included in the European Ath-
erosclerosis Society (EAS), European Society of
Cardiology (ESC), and European Society of Hyper-
tension (ESH) guidelines. The average consumption
of mono-unsaturates in Italy fluctuates between 18
and 20% of total fatty acids.Polyunsaturated fatty acids of the
n-6 series
PUFAs of the n-6 series (which occur widely in
food, essentially as linoleic acid, and in particular
in some seed oils, such as corn, sunflower, and
soybean oils) induce a documented cholesterol-
lowering effect. This is about half the hypercho-
lesterolemic activity of saturates according to
equations such as that of Hegsted et al. [9]. This
effect of n-6 polyunsaturates was first noted in
the 1950s, during early studies to assess the ef-
fects of fatty acids upon cholesterolemia. In gen-
eral, a 1% increase of n-6 polyunsaturates
ingested with the diet leads to a mean reduction
of total plasma cholesterol levels of approximately
1 mg/dl [13].
Linoleic acid (the 18-carbon precursor of the n-6
series) is thus generally considered as hypocholes-
terolemic, especially when compared with oleate
or saturates. This fatty acid, unlike monounsatu-
rates, does not have significant effects on plasma
HDL cholesterol levels. The ability of linoleic acid
to affect LDL-C might arise from an increased
expression of such lipoproteins’ receptors in the
liver [14].
These data are indirectly confirmed by the
observation that consumption of polyunsaturates
of the n-6 series is associated with a significant
reduction of cardiovascular risk in most
epidemiological studies and in some controlled
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risk for women in the highest quintile of consump-
tion is reduced by 30%, as compared with women in
the lowest quintile [15].
Based on these data, in 2001 the US ATP-III
recommended an optimal intake of total polyun-
saturates (n-6 þ n-3) up to 10% of the total calories
for cholesterolemia control. This amount includes
approximately 2 g (i.e., 1% of total calories) of n-
3 fatty acids. It should be stressed that, according
to recent studies, polyunsaturates consumption in
Italy is much lower, at 3e6% of total calories [16].Polyunsaturated fatty acids of the
n-3 series
The n-3 fatty acids are found in nuts and vegeta-
bles as alpha-linolenic acid (ALA) and in marine
products as eicosapentaenoic acid (EPA), and
docosahexaenoic acid (DHA). Their intake mainly
affects triglyceride-rich lipoproteins [very low
density lipoproteins (VLDLs)], whose synthesis
and hepatic excretion are reduced. Consequently,
n-3 fatty acid intake tends to decrease plasma
triglyceride levels. This effect is more pronounced
in patients with elevated basal plasma triglyceride
levels and can be accompanied by an increase in
plasma LDL cholesterol levels, usually of lower
magnitude [17]. The effects n-3 fatty acids have on
VLDL metabolism, which occur through different
mechanisms, include the reduction of VLDL secre-
tion and triglyceride transport, with the formation
of smaller VLDLs and, likely, an increased VLDL
clearance. The main mechanism of action is the
reduced availability of fatty acids for incorpora-
tion into triglycerides because of the increased
beta-oxidation, reduced synthesis through the in-
hibition of key enzymes, and the modulation of
membrane composition.
Some studies showed a positive effect of n-3
fatty acids, such as fish oil, on plasma HDL
cholesterol levels, namely via increased HDL2
(larger and richer in cholesterol) and reduced
HDL3 levels. However, the results are not consis-
tent and other studies reported limited or no ef-
fects of n-3 fatty acids on these parameters [18].
Similarly, most studies concur that the effects
of n-3 fatty acids on total and plasma LDL choles-
terol levels are negligible. Qualitatively, supple-
mentation with EPA and DHA leads to the
formation of larger (hence less atherogenic)
LDLs, possibly through the inhibition of cholesteryl
ester transfer protein (CETP) [19].
Some authors propose the assessment of n-3 and
n-6 fatty acid intake not only in absolute terms,but also as a ratio between these two fatty acid
classes. The rationale lies in the inhibitory activity
of n-6 (when in very high proportion) on n-3
metabolism and the proposed pro-inflammatory
environment that results. However, the available
data do not support a significant correlation
between a high n-6 to n-3 ratio and inflammatory
markers; a role for the n-6 to n-3 ratio in the
control of cholesterolemia has also not been
convincingly demonstrated.Unsaturated fatty acids with trans
conformation
Nearly absent in vegetables (in which double bonds
always have a cis conformation), trans fatty acids
can be found in limited amounts (usually <5% of
total fat) in dairy products and in meats from rumi-
nants. However, the major sources of trans fatty
acids in Western countries are the ‘partially hydro-
genated fatty acids’ of industrial origin. Marked
amounts of trans fatty acids are formed when
oils are solidified to produce margarine [20]. Indus-
trially derived trans fatty acids tend to increase
total and plasma LDL cholesterol levels, and re-
duce plasma HDL concentrations. Quantitatively,
trans fatty acids increase plasma LDL cholesterol
levels by 1.2 mg/dl and reduce HDL levels by
0.6 mg/dl for each 1% increase in their consump-
tion as isocaloric substitution for carbohydrates.
The effects of trans fatty acids are thought to
occur through their inhibitory effects toward
peroxisome proliferator activated receptor (PPAR)
alpha, a nuclear receptor that controls the tran-
scription of genes which code for a number of apo-
proteins and enzymes (e.g., lipases), involved in
multiple aspects of lipid metabolism [20].
Moreover, trans fatty acids appear to induce
a potentially deleterious pro-inflammatory activ-
ity. The metabolic effects of trans fatty acids pro-
duced by ruminants, and found in milk and dairy
products, are understood less well.
Evidence from prospective studies indicates
that the increased consumption of trans fatty
acids of industrial origin increases the risk of car-
diovascular disease. In the Nurses’ Health Study,
women in the highest quintile of consumption
had a risk of fatal and non-fatal events that was
50% higher at the first follow-up and 33% higher
at the subsequent follow-up [15].
Most recent margarines (usually softer and
easier to spread) have low or negligible concen-
trations of trans fatty acids, whereas the ‘old
generation’ harder margarines used to contain
up to 40% of these compounds. Fat that is
6 A. Poli et al.trans-rich is still employed in several pastry and
bakery products, especially those of artisan
manufacture, because of their low cost, high
stability, and favorable technological features.
A recent statement of the American Heart Associ-
ation (AMA) suggests that the total intake of trans
fatty acids should not exceed 1% of the total ca-
loric intake (i.e., 2e2.5 g/day). In 2002, the Insti-
tute of Medicine in the USA stated that trans
intake should be as low as possible, since no im-
portant physiological role is known for these fatty
acids.Key points
A lipid intake of 30e35% of total calories is
probably adequate to control total and plasma
LDL cholesterol levels in Western countries,
and specifically in Italy. Based on the nutri-
tional habits in Italy and other Mediterranean
countries, it is advisable to use mainly extra
virgin olive oil as the dietary fat of choice,
even though its effects on total and plasma
LDL cholesterol levels are modest. Saturates
intake should be limited to 7e10%, while trans
intake should be limited to those from dairy
products only. The use of seed oils rich in n-
6 polyunsaturates improves total and plasma
LDL cholesterol levels; consequently, polyun-
saturates can contribute up to 7e10% of total
calories, including 1% of n-3 polyunsaturates
(which do not modify total and plasma LDL
cholesterol levels).
Key points
The most recent evidence puts a new perspec-
tive on the role of dietary cholesterol in cho-
lesterolemia management. Even if it may
seem advisable not to exceed a daily choles-
terol intake of 300 mg, it is unwise to reduce
dramatically or eliminate cholesterol-rich
foods such as eggs.Dietary cholesterol and cholesterolemia
The exact roles and contributions of dietary
cholesterol to cholesterolemia and atherogenesis
are still debated. Indeed, it has been proved that
dietary cholesterol increases plasma LDL choles-
terol levels; however, this effect is much less
prominent than that of saturated or trans fatty
acids. Finally, whether the intake of dietary
cholesterol affects cardiovascular risk is still un-
certain [2].
Cholesterol is only present in animal-derived
food items. For instance, high cholesterol levels
are found in bovine liver, brain and tripe, in eggs,
and in crustaceans. Bread, pasta, rice, and vege-
table oils are devoid of cholesterol. Of course,
food items that contain eggs and butter also
contain cholesterol.A meta-analysis of 395 studies, carried out to
determine the influence of exogenous cholesterol
on plasma lipids, found that a decrease of 200 mg/
day in cholesterol consumption leads to a 5 mg/dl
decrease in total plasma cholesterol levels and, in
particular, to a 3.8 mg/dl decrease in plasma LDL
cholesterol levels [3]. Patients with mixed hyperli-
poproteinemia appear to be more sensitive to ex-
ogenous cholesterol than patients with isolated
hypercholesterolemia. After a cholesterol-rich
diet (e.g., with elevated egg consumption), in-
creases in plasma LDL cholesterol levels are
smaller in insulin-resistant patients than in those
who are not resistant to insulin. This difference
might result from the reduced cholesterol absorp-
tion in the former, who behave as ‘cholesterol
synthesizers’.
The wide inter-individual variability of choles-
terol absorption (from w30 to w80%) and the
contribution of biliary cholesterol (w1 g/day),
which is greater in absolute terms and non-modifi-
able, also make it difficult to determine the exact
contribution of dietary cholesterol to its circulat-
ing concentrations. This inter-individual variability
is likely a consequence of specific genetic polymor-
phisms that can affect the plasma lipid profile in
response to diet. Carriers of the e4 allele of
apoE, as an example, respond better to dietary
cholesterol restriction in terms of LDL-C reduction
and increase in plasma HDL cholesterol levels [21].
The AHA guidelines prudently recommend lim-
iting cholesterol intake to less than 300 mg/day in
the general population and to less than 200 mg/
day in hypercholesterolemic, diabetic, or cardio-
vascular patients. Other health authorities, such
as those of Canada, recommend a saturated fat in-
take of less than 10% of total calories, but do not
intentionally indicate an upper limit of cholesterol
intake.
Nonetheless, limiting dietary cholesterol intake
makes sense, even though some cholesterol-rich
foods, such as eggs, are of important nutritional
value.
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Several reports demonstrate that substituting sat-
urated and trans fatty acids with carbohydrates
leads to a reduction of total and plasma LDL cho-
lesterol levels. However, increasing carbohydrate
dietary intake can bring about deleterious effects
on plasma lipids, such as increased plasma triglyc-
eride levels e which might be an independent risk
factor for cardiovascular disease e and increased
concentrations of small, dense LDLs, along with
decreased plasma HDL cholesterol levels [2]. A re-
cent meta-analysis performed on 60 controlled tri-
als concludes that increased carbohydrate
consumption, as isocaloric substitution for fat, is
associated with a decrease in plasma HDL choles-
terol levels [22].
Several lines of evidence differentiate the
effects on lipid metabolism of mono- and disac-
charides from those of polysaccharides. Simple
sugars, namely sucrose and fructose, may increase
plasma triglyceride concentrations; high sucrose
intake has also been associated with decreased
plasma HDL cholesterol levels. This latter effect is
explained by the increase in plasma triglyceride
concentrations, because the enrichment of HDL
with triglycerides enhances their catabolism. Con-
versely, mono- and disaccharides do not signifi-
cantly affect plasma LDL cholesterol levels [23].
Currently, the glycemic index (GI, the relative
glycemic response to a food compared with white
bread or pure glucose) and the glycemic load (GL,
which also takes into account the amount of
carbohydrate consumed) of a food item are consid-
ered the most functionally relevant parameters of
carbohydrates and of carbohydrate-rich foods [24].
It is known that the blunting of postprandial
glycemia and insulinemia associated with the
consumption of low-GI food ameliorates insulin
sensitivity and reduces the hepatic synthesis and
secretion of triglycerides, which leads to lower
concentrations of triglyceride-rich lipoproteins
and increased plasma HDL cholesterol levels [25].
Several studies have demonstrated that the
substitution of saturated fat with low-GI carbohy-
drates does not lead to the increased plasma
triglyceride levels and reduced plasma HDL cho-
lesterol levels usually associated with a diet rich in
high-GI carbohydrates [26].
Two cross-sectional studies [27,28] have also
demonstrated that plasma HDL cholesterol levels
is inversely correlated with the average GI of
a usual diet. Low-GI diets e often rich in soluble fi-
bers e also induce a modest, though reproducible,
hypocholesterolemic effect.International guidelines advise that total carbo-
hydrates make up for 50e60% of total calories;
simple carbohydrates should not exceed 10% of the
daily caloric intake. However, if fatty acids with
favorable effects on plasma lipids (MUFAs and
PUFAs) are selected, even diets with less than
50% carbohydrates may induce a positive effect on
plasma cholesterol levels.
Dietary fiber also induces notable effects on
plasma lipids and lipoproteins. This effect is more
pronounced for soluble or gel-forming fibers (i.e.,
pectins, gum, beta-glucans, mucilages, and hemi-
cellulose) for which the dietary sources are ce-
reals, such as barley and oat, and legumes. The
consumption of 5e10 g/day of soluble fiber, such
as beta-glucans, glucomannan, guar, and psyllium,
reduces plasma LDL cholesterol levels byw5% [8].
A meta-analysis [29] concluded that each gram of
soluble fiber reduces total plasma cholesterol
levels by w2 mg/dl and plasma LDL cholesterol
levels by w2.5 mg/dl, with small variations due
to study groups and doses. Fiber reduces choles-
terol absorption by the ileum and increases fecal
excretion. For psyllium (but not other fiber types),
partial impairment of the enterohepatic circula-
tion of bile salts has also been demonstrated.
The US Food and Drug Administration (FDA)
allowed the claim of a ‘reduction of cardiovascular
risk’ (within a low-cholesterol and saturated fat
diet) for psyllium extracted from Plantago psyl-
lium and, more recently, for beta-glucans of oat
and barley.
By contrast, soluble fiber does not induce
significant effects on plasma concentrations of
triglycerides and HDL-C.
A Cochrane Collaboration review [30] recently
analyzed the randomized trials that specifically as-
sessed the effects of whole cereals (the major
source of soluble fibers) on lipid risk factors for
cardiovascular disease. In particular, eight studies
that examined the effects of oat and its deriva-
tives on lipid profile clearly indicated their effec-
tiveness in reducing plasma LDL cholesterol
levels. No variations of plasma triglyceride levels
and plasma HDL cholesterol levels were observed.
In general, studies carried out with carbohy-
drate- and fiber-rich diets showed that these also
led to modest reductions of body weight, probably
through the satiating effects of bulky food with
low caloric load. The reduction of body weight
along with the effects of fibers might partly
explain the less atherogenic profile associated
with this kind of diet.
The most recent international guidelines [ATP-
III [8], AHA 2006 [31]] recommend an increased
8 A. Poli et al.consumption of fiber-rich food to achieve a daily
intake of 30 g.
Some guidelines suggested that such a target
amount could be reached using fiber supplements
in doses that range from 5 to 10 g/day. However,
at present there is no evidence that supplements
provide the same effects as whole foods. Based
on current data, consumption of the latter (includ-
ing whole grains, which may favorably affect
cardiovascular heart disease (CHD) risk via addi-
tional biological mechanisms) is preferable over
the use of the former or of purified fiber.Key points
Absorbable dietary carbohydrates do not play
a major role in the control of total and plasma
LDL cholesterol levels, even though they can
reduce the levels of these when they replace
hypercholesterolemic fat, namely saturated
and trans fatty acids.
On the other hand, low-GI foods may help to
ameliorate, though to a limited extent,
plasma HDL cholesterol levels and to reduce
plasma triglyceride levels.
A daily fiber intake of 25e30 g may play a sig-
nificant hypocholesterolemic role; soluble and
gel-forming fiber is more effective than non-
soluble fiber, and increasing its intake by
5 g/day can reduce total and plasma LDL cho-
lesterol levels.
Key points
A moderate ethanol intake (<40 g/day in men
and <25 g/day in women) increases plasma
HDL-C levels.
Dietary protein does not appear to induce sig-
nificant effects on plasma total cholesterol or
fractions thereof.
Calcium (and possibly magnesium) and garlic
supplements may help to lower plasma choles-
terol, but published data conflict.
Vitamins, other minerals, and soy lecithin do
not significantly affect plasma total or LDL-C
levels.Interventions on other macro- and
micronutrients
Few other nutrients appear to induce a discernible
effect on lipoprotein patterns.
Ethanol consumption at doses that may be re-
garded as ‘moderate’ (30e40 g/day in men,
15e25 g/day in women) is associated with signif-
icantly higher HDL cholesterol levels than those
found in non-drinkers. This effect is seen on both
main HDL subfractions (HDL2 and HDL3) and may
be directly elicited by ethanol through increased
synthesis of apolipoprotein A-1 (apoA-I), the major
apolipoprotein present in HDL [32].
High ethanol intake may sometimes increase
plasma triglyceride levels, in particular in subjects
already hypertriglyceridemic at baseline, but on
average the effect of moderate ethanol doses on
plasma triglyceride levels is not significant [33].
The action of ethanol on HDL lipoproteins may
account for about half of the reduction in coronaryand cardiovascular risk associated with moderate
ethanol consumption in observational studies [34].
The effect of dietary protein on cholesterol
levels appears to be modest [2]. Although vegeta-
ble protein is traditionally believed to reduce cho-
lesterolemia when substituted for animal protein,
it is difficult to assess the effect of vegetable pro-
tein independently from that of other vegetable
components with established cholesterol-lowering
action, such as fiber. Likewise, it is difficult to
dissect the individual contribution of vegetable
protein because its consumption substitutes for
nutrients (i.e., animal fat) known to increase total
and LDL-C levels. In the OmniHeart study, how-
ever, partially substituting protein for carbohy-
drates led to modest but statistically significant
beneficial changes in plasma total and LDL-C, as
well as in triglyceride levels [35].
Specific data are available for soy protein as
discussed below.
Some studies suggest a possible effect of garlic
on total and LDL-C values, but literature reports
are inconsistent [36]. Similarly, other reports high-
light a beneficial effect of calcium (and possibly
magnesium) on cholesterolemia, likely to be be-
cause of the ability of these bivalent cations to
bind fatty acids, triglycerides, and cholesterol in
the gut, and thereby limit their absorption [37].
In contrast, vitamins, otherminerals, soy lecithin
and the like have no significant influence on plasma
total cholesterol and, in particular, on LDL-C [38].Body weight changes and
cholesterolemia
Obesity is involved in the development of a number
of chronic degenerative diseases and leads to
Key points
In most available studies, body-weight control
can reduce significantly, albeit not dramati-
cally, plasma total and LDL-C levels, especially
in obese subjects. In addition, a decline in
triglycerides is usually observed; HDL-C levels
tend to rise on sustained weight loss.
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mechanisms. In this regard, the most recent
studies have turned the spotlight on abdominal
obesity, often associated with atherogenic dyslipi-
demia (low HDL-C and elevated plasma triglycer-
ide levels, along with hyperinsulinemia and
arterial hypertension).
The same alterations in plasma lipid profile,
however, occur in overweight or obese patients as
defined by body mass index (BMI) criteria. Accord-
ingly, the correlation between BMI and LDL-C
values is rarely significant in observational studies,
whereas the positive correlation between BMI and
triglycerides and the negative correlation with
HDL-C generally reach statistical significance,
even in multivariate analysis.
Studies that examined the effects of weight loss
on plasma total cholesterol or lipid patterns in-
dicate that weight loss is basically associated with
a modest, yet statistically significant, decrease in
plasma total and LDL-C levels, whereas the effects
on triglycerides are usually more pronounced.
Changes in HDL-C are diverse [39].
The conclusions of a systematic review that
encompassed 70 studies designed to induce
weight reduction and detect changes in plasma
lipid levels indicated that weight loss per se (aver-
aging 16 kg or 16% from baseline weight) is associ-
ated with a mean decrease in plasma total
cholesterol of about 30 mg/dl, with LDL and
VLDL cholesterol dropping in equal proportions
[40]. Overall, significant correlations are found
between weight reduction and decreased plasma
total cholesterol, LDL-C, VLDL cholesterol, and
triglyceride concentrations. For every kilogram
decrease in body weight, total and LDL-C levels
are reduced by 2 mg/dl and 0.8 mg/dl, respec-
tively. Furthermore, a 0.3 mg/dl reduction in
HDL-C occurs for subjects who actively lose
weight, whereas a 0.4 mg/dl increase occurs for
subjects at a stabilized weight. A more recent
meta-analysis showed that a drop in LDL-C con-
centration for every 10 kg of weight loss amounts
to 8.8 mg/dl in grossly overweight/obese sub-
jects, which substantially confirms the above con-
clusions [41]. Furthermore, weight loss is known
to lower cardiovascular risk through additional
mechanisms (such as improved glycemic and
blood pressure control).
Not all the studies, however, are consistent.
Data from the Swedish Obese Subjects (SOS) study
indicate that an average weight loss of 33% at two
years after bariatric surgery decreased plasma
triglyceride concentrations and increased plasma
HDL-C concentrations without affecting plasma
total cholesterol [42].Improvements in HDL-C and in plasma triglycer-
ide levels tend to be greater in overweight or
obese subjects on low-carbohydrate diet, whereas
changes in LDL-C levels were more favorable in
subjects on low-fat diets [43].Physical activity and cholesterolemic
control
The findings from epidemiological observations
clearly indicate that physical inactivity remarkably
increases the odds of many chronic degenerative
diseases, including cardiovascular disease. Regular
physical activity is beneficial for many risk factors
of the above clinical conditions as it improves the
plasma lipid profile and also aids, for instance,
overweight and hypertension control [44]. How-
ever, a sedentary lifestyle (a good proxy for which
may be the time spent watching television) is also
a strong marker of a poor lipid profile, indepen-
dent of the person’s physical activity [45]. Obser-
vational studies indicate that the impact of
physical activity on lipid fractions is greatest for
HDL-C, which tends to increase, and for triglycer-
ides, which tend to fall in active individuals as
compared with inactive controls. The increase in
HDL-C levels observed in active with respect to
sedentary subjects varies from 9 to 50% and tri-
glyceride reduction ranges from 19 to 50% [46].
By contrast, changes in plasma total and LDL-C
values are less consistent and wane in many
studies after adjusting for other lifestyle compo-
nents (dietary habits, smoking, and alcohol con-
sumption among others) using multivariate
analysis.
Most observational studies show a close relation-
ship between total ‘amount’ of physical activity
and the resultant changes in plasma lipid profiles.
Significant concentration changes in plasma lipid,
however, may not be achieved until a distinct
threshold is met. This threshold is not clear-cut
and varies across different studies from 700 to
10 A. Poli et al.2000 kcal/week (which corresponds to about 11e
32 km/week of brisk walking or jogging), with fur-
ther benefits likely to occur above 3000 kcal/
week [47,48]. Aerobic physical activity, such as
walking, jogging, cycling, or swimming, with total
energy expenditure of 1500e2200 kcal/week
(which corresponds to about 24e32 km of brisk
walking or jogging per week) may increase plasma
HDL-C levels by 3.5e6 mg/dl and lower plasma tri-
glyceride levels by 7e20 mg/dl. A further 16 km/
week would trigger an additional 3 mg/dl increase
in plasma HDL-C levels and an additional 3e8 mg/
dl drop in plasma triglyceride concentrations.
A similar scenario emerges from a review of
some 100 prospective intervention studies per-
formed between 1974 and 1999. These studies
included exercise interventions based on aerobic
activity, usually cycling, walking, or running, with
intensities >60% of maximum heart rate or VO2 in
an ergometric test.
Exercise training was reported to alter total and
LDL-C levels in just over25%of the studies and induce
reductions, if any, of 4e7%. PlasmaHDL-C rose by 2e
8 mg/dl (w5e20%), whereas plasma triglyceride
levels decreased by 5e38 mg/dl (w5e20%). These
effects were more pronounced in males and in
previously sedentary individuals. Conversely, resis-
tance exercise programs do not significantly modify
plasma lipids [46], but may increase lean muscle
mass and insulin sensitivity, and reduce the gain in
waist circumference associated with aging [49].
A prospective, randomized study compared the
effect of three training programs of exercise: large
amount of high intensity; large amount of moder-
ate intensity; and small amount of moderate
intensity. At the end of the program, exercise
training increased the size and concentration of
HDL particles and decreased plasma triglycerides,
but had no significant effect on the total or LDL-C
concentrations. The high-intensity, high-amount
exercise group showed the most improvement in
lipid profiles [50].Key points
Regular aerobic physical activity generally in-
duces an increase in plasma HDL-C and a de-
crease in plasma triglyceride levels, whereas
the effects on total and LDL-C are inconsistent
and generally modest. This effect is, to some
extent, dose-dependent and the efficacy
threshold is set at 1500 kcal/week (equivalent
to about 24 km of brisk walking or jogging per
week).Interventions to enhance the
cholesterol-lowering action
of an appropriate diet
Interventions on dietary macronutrients (essen-
tially lipids) typically induce decreases in plasma
total and LDL-C levels that range from 5 to 10%. If
this does not lower plasma cholesterol to the
target values in individuals according to their risk
level, in the absence of compelling indications for
hypolipidemic pharmacological treatment it is
possible to use strategies that boost the choles-
terol-lowering action of the above dietary ap-
proaches. Implementing such interventions is not
intended to replace the dietary interventions de-
scribed above, which should be continued. These
‘additional’ strategies may sometimes be per-
ceived by the lay public as possible ‘shortcuts’ to
avoid a change in dietary habits (or to avoid
compliance with such changes in the long term).
Physicians and health-care professionals should
provide adequate counseling and recommend their
use only if targeted common dietary modifications
fail to attain anticipated goals.
In this context, controlled studies have been
performed mainly with plant sterols and soy pro-
tein. The consumption of foods enriched in plant
sterols or soy protein requires sustained adherence
to ensure plasma cholesterol levels do not return
to baseline.Phytosterol-enriched food products
and plasma cholesterol control
Phytosterols (or plant sterols and stanols) are
hydrophobic molecules that are structurally re-
lated to cholesterol. They occur naturally in
vegetable oils and, in smaller amounts, in vegeta-
bles, fresh fruits, chestnuts, grains, and legumes.
The dietary intake of plant sterols does not usually
exceed 250e300 mg/day in Northern European
countries, whereas it appears to be higher (up to
500e600 mg/day) in Mediterranean countries [51].
Plasma total phytosterol levels in humans are
very low, in the range from 1 to 2 mg/dl. Despite
their significant initial absorption from the intesti-
nal tract via the same efficient pathway that medi-
ates cholesterol absorption, phytosterols are
almost completely returned to the intestinal lu-
men through specific transporters. As a result,
their net absorption is much lower than that of
cholesterol (0.02e3.5% vs 35e70%) [52].
The interest in phytosterols lies in their ability
to compete with cholesterol for intestinal
Key points
Incorporation of food products that contain 2 g
of phytosterols into the diet reduces plasma to-
tal and LDL-C levels by about 10% without sig-
n ificant effects on plasma HDL-C and
triglycerides. Their consumption should be
linked to the principal meal(s) and be contin-
ued for a long time.
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and food-derived cholesterol for micelle formation
in the gut. The ability of phytosterols to modulate
dietary cholesterol absorption entails a decrease
in plasma cholesterol levels, in particular the LDL-
bound fraction, through a partially dose-depen-
dent mechanism [53].
The correlation between use of different doses
of phytosterols and the reduction of plasma LDL-C
levels was examined in several studies published
between 1998 and 2006, as well as in one meta-
analysis [54]. Available data suggest that plasma
LDL-C reductions increase with phytosterol doses,
at least in the range from 0.7 to 2.0e2.5 g/day;
the use of higher doses provides no additional ben-
efits in terms of plasma cholesterol reduction and
is therefore not advisable.
Based on recent data, food matrices do not
appear to affect significantly the cholesterol-low-
ering efficacy of phytosterols at equivalent doses.
Phytosterols do not appear to be more effective if
ingested in several daily doses during meals,
whereas linking the time of ingestion to a principal
meal is markedly more effective than consumption
not linked to meals [55].
Long-term efficacy studies have shown that the
cholesterol-lowering effect of phytosterols usually
becomes apparent after three weeks and is sus-
tained upon regular consumption. Furthermore,
their effect on the lipid profile is additive to that
of lipid-lowering diets and does not change in
subjects treated with statins and/or fibrates,
which thereby reduces the plasma LDL-C levels
achieved with pharmacological treatment by a fur-
ther 8e10%.
A relevant issue in the use of phytosterols,
which is necessarily chronic, is their long-term
safety. A number of studies have shown that
changes in the plasma levels of several lipophilic
vitamins and nutritional or non-nutritional factors
are insignificant. By contrast, a 7e17% decline in
the plasma levels of b-carotene after adjustment
for LDL reduction was observed for as yet unclear
reasons, although this may be controlled by in-
creasing the intake of fresh high-carotenoid vege-
tables [56].
Based on the elevated coronary disease risk in
the very few patients with phytosterolemia caused
by mutations in the ABC G5/G8 transporters, some
authors have raised the possibility that the modest
increase in the plasma concentration of phytos-
terols in subjects treated with 2 g/day thereof may
be atherogenic. The three published case-control
studies that compare subjects with and without
a history of coronary disease, however, are not
consistent (the risk increased in one study,remained unchanged in the second, and decreased
in the third) and, therefore, do not support this hy-
pothesis [57].
Based on the available information, it is thus
reasonable to concur with the NCEP ATP-III guide-
lines published in 2001 [58], which recommend
a daily intake of 2 g/day of phytosterols and/or
phytostanols to achieve an additional plasma
LDL-C reduction when dietary interventions are
not successful. Similar recommendations were in-
corporated in the Australian guidelines for lipid
control and the Finnish Medical Society guidelines
in 2004.Soy protein
Soy-derived protein displayed significant choles-
terol-lowering activity in clinical studies that in-
volved patients with different forms of
hypercholesterolemia. A meta-analysis in 1995
[59] reported that soy protein, when partially or
fully substituted for dietary animal protein, in-
duced a mean decrease of 23 mg/dl in plasma total
cholesterol concentrations and of 22 mg/dl in LDL-
C concentrations. The observed reduction was re-
lated to the initial plasma cholesterol concentra-
tions, that is it was greater in subjects with
established hypercholesterolemia and minor or
negligible in those with baseline cholesterolemia
below 230 mg/dl. This set of data has been recon-
firmed by a new meta-analysis published recently
[60].
Based on the available scientific evidence, in
1999 the US FDA released a claim that a daily
dietary supplementation with four soy-protein
servings (6.25 g each) may significantly reduce
the risk of cardiovascular disease [61]. At these
doses, the average fall in plasma cholesterol levels
is about 10%, depending on the baseline cholester-
olemia (as noted above) and is mostly accounted
for by the reduction in LDL-C, whereas HDL-C
and plasma triglyceride levels are essentially un-
changed after treatment.
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component is almost certainly protein, whereas
isoflavones do not appear to contribute signifi-
cantly to the effects on lipid metabolism. The
cholesterol-lowering effect may be attributable to
the ability of soy protein to upregulate the
expression of apo-B receptors [62,63].
Based on early preclinical studies, Lupinus albus
protein may also provide an interesting option to
develop cholesterol-lowering foods [64].Key points
Including 25 g of soy protein in the diet as
a partial replacement of animal protein re-
duces plasma total and LDL-C concentrations.
The beneficial effects are proportionally
greater in subjects with hypercholesterolemia;
no significant effects are observed on HDL-C
and plasma triglyceride levels.
Key points
In women, the diet should be targeted not
only at coronary risk reduction through plasma
cholesterol control, but also at the prevention
of osteoporosis. Both aims can be achieved
through foods with low fat and adequate cal-
cium content, optimal vitamin D intake, and
regular physical activity.Simultaneous prevention of coronary
heart disease and osteoporosis in
postmenopausal woman
Appropriate assessment of the dietary lipid intake
is also important to meet an adequate daily
calcium requirement. Milk and dairy products
(yogurt, cheese, and ice cream) represent the
major source of calcium. This issue is crucial, in
particular for women who need to prevent osteo-
porosis and its complications as well as to prevent
coronary heart disease through the control of
plasma cholesterol levels.
Daily calcium requirements vary throughout an
individual’s lifetime and rise from 1200 mg/day in
fertile women to 1500 mg/day in postmenopausal
women. However, epidemiological studies, which
include some from Italy, reported a low average
calcium intake in the daily diet [65].
Although women should be advised to increase
their calcium intake and consider primarily milk
and dairy products for this purpose, it is important
to take into account that these foods (especially
cheese) may contain large amounts of saturated
fat and may therefore worsen the cardiovascular
risk profile, particularly plasma total and LDL-C
levels. Dietary prevention of osteoporosis should
focus not only on calcium intake, but also on
reducing animal protein and increasing the amount
of basic foods that are able to buffer excess acid in
plasma, which in turn stimulates bone calcium
mobilization [66].It is therefore advisable to adopt a diet with
adequate calcium content while at the same time
limiting the total lipid intake. However, adequate
calcium levels may be found in low-fat foods such
as skimmed or partially skimmed milk and low-fat
yogurts (which contain slightly larger calcium
amounts than whole milk and yogurt). They are
also found in specific dairy products (cottage
cheese, ricotta cheese from cow’s and sheep’s
milk), in specific types of fish and shellfish
(anchovies, squid, octopus, horse mackerel, mus-
sels, striped sea bream), and in specific vegeta-
bles and seeds (rocket, green chicory, mustard
greens, endive). Calcium from all these foods,
unlike that found in grains, beans, and other
vegetables, is readily absorbed because of the
low oxalate and phthalate content. A remarkable
amount of calcium may also be obtained from
mineral waters that contain at least 150e200 mg
calcium per liter [67].
It should be recalled, however, that calcium
absorption occurs only partially (by an estimated
8e23%) through passive diffusion, which is related
to dietary calcium intake. In contrast, the major
pathway of calcium absorption is dependent on
vitamin D. Daily sunlight exposure usually provides
adequate vitamin D supply; however, vitamin D is
also present in some low-fat (i.e., mushrooms) and
medium-fat foods, such as eggs and, in particular,
some types of fish (i.e., anchovies, herring,
salmon, sardines, dripped olive-oil tuna). In these
fish types, vitamin D levels range from 5 to 19 mg
per 100 g edible parts.
Thus, a balanced diet combined with ade-
quate sunlight exposure and physical activity
(the latter is also relevant to osteoporosis pre-
vention), can improve outcomes not only in
patients with hypercholesterolemia and other
cardiovascular risk factors, including obesity,
diabetes and arterial hypertension, but also in
those with hallmarks of osteopenia or established
osteoporosis.
Key points
A Mediterranean-like diet seems to influence
the cardiovascular risk positively, probably
via mechanisms not entirely explained by the
effects on the plasma lipid profile.
The effect of such a dietary model on choles-
terol levels can be enhanced, whenever nec-
essary, by specific interventions or the use of
fortified foods.
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cholesterol control
In 1993, the International Conference on the Diet
of the Mediterranean [68,69] summarized the key
elements of this diet at follows:
1) abundant plant foods (fruits, vegetables, breads,
other forms of cereals, beans, nuts, and seeds);
2) minimally processed, seasonally fresh, and lo-
cally grown foods;
3) fresh fruits as the typical daily dessert with
sweets based on nuts, olive oil, and concen-
trated sugars or honey during feast days;
4) olive oil as the principal source of dietary lipids;
5) dairy products (mainly cheese and yogurt) in
low-to-moderate amounts;
6) fewer than four eggs per week;
7) red meat in low frequency and amounts;
8) fish and poultry in low-to-moderate amounts;
9) wine in low-to-moderate amounts, generally
with meals.
However, countries around the Mediterranean
basin have different dietary patterns, even though
the current process of globalization and lifestyle
modification is slowly altering the dietary habits of
each country. Thus, there is no uniform ‘Mediter-
ranean diet’ and, indeed, the term ‘Mediterranean
diet’ may be considered a misnomer. It refers
specifically to the dietary pattern observed in the
early 1960s in areas of Southern Italy and Greece
and on the island of Crete. This diet is precisely
associated with these traditionally olive-growing
areas. Indeed, the use of olive oil as the major and
often exclusive fat source is unique to the Medi-
terranean area. From the nutritional viewpoint,
the use of olive oil (which was recently granted an
FDA health claim of cardioprotective activity) en-
ables the intake of saturated fatty acids (except
short-chain ones from dairy products) to be limited
as they can be replaced with monounsaturates such
as oleic acid. Consumption of n-6 PUFAs is also low.
The Mediterranean nutritional pattern also in-
cludes a high intake of fiber and ‘functional’
phytochemicals from plant foods, among which
phytosterols (from seed oils and cereals) are of
particular importance and of which, on average,
400 mg/day are consumed. The Mediterranean diet
features most of the indications for plasma choles-
terol control outlined in this paper, with some
exceptions. Actually, this diet only includes a low-
to-moderate amount of n-6 PUFAs, mostly from
seed oil (soy, sunflower, corn, rapeseed, peanut,
and sesame), that can contribute to the control oftotal and plasma LDL cholesterol levels. Moreover,
the Mediterranean diet provides a rather high per-
centage (25e35%) of calories from fat, in contrast
to most nutritional guidelines (30% of daily calo-
ries). However, a moderate increase of calories
from fat, if derived from MUFAs, is considered fa-
vorable by most investigators and some authorita-
tive guidelines. The increase in MUFA can also
positively influence health-related parameters
other than the lipid profile, such as insulin sensitiv-
ity. A shift ofw10% of calories from carbohydrates
to calories from MUFAs is currently adopted as die-
tary therapy for the metabolic syndrome and type II
diabetes, as it reduces plasma triglyceride levels
without influencing plasma HDL cholesterol levels.
Several studies support the positive effects of the
Mediterranean regimen on plasma lipid profile (re-
duction of total and plasma LDL cholesterol levels,
plasma triglyceride levels, and apo-B and VLDL
concentrations, and an increase in plasma HDL
cholesterol levels). This effect is associated with
increased plasma antioxidant capacity, improved
endothelial function, reduced insulin resistance,
and reduced incidence of the metabolic syndrome.
In general, theMediterraneandiet reduces the risk of
CHD, an effect that is not completely explained by its
action on the lipid profile and is, in part, attributable
to further non-lipid pathways [69e71]. Additional
studies built on evidence-based methodologies are
necessary to draw conclusions, in particular to
discern the individual effects of dietary components
from those of the diet as a whole.
In conclusion, the Mediterranean diet can rep-
resent, in Italy, the most appropriate base for
a nutritional strategy aimed to prevent cardiovas-
cular diseases. In specific cases its effects on total
and plasma LDL cholesterol levels may be aug-
mented via selective adjustments of the lipid
intake or through ad hoc supplementation with
functional foods, implemented whenever possible
on the grounds of personal diet characteristics. Ex-
cept for specific cases, such interventions should
precede any pharmacological action.
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The levels of evidences and the grades of
recommendation regarding the lipid effect of
the main dietary and life-style interventions
described in this paper, prepared according
to the SIGN protocol [72], are summarized in
Table 1.Table 1 Levels of evidence and grades of recom-
mendation regarding the lipid effect of some of the
nutritional and life-style interventions examined in
the paper
Dietary recommendation Grading SIGN
Diminution in saturated fatty acids
intake reduces total and LDL
cholesterol
A, 1þ
Increased n-6 PUFA intake
decreases total and LDL
cholesterol
A, 1þ
Trans-unsaturated fatty acids
intake diminution decreases total
and LDL cholesterol and increases
HDL cholesterol
B, 2þþ
Dietary cholesterol intake
reduction decreases total and
LDL cholesterol
B, 2þþ
Low GI foods intake increases HDL
cholesterol
B, 2þ
High fiber diets decrease total and
LDL cholesterol levels
A, 1þ
Weight reduction slightly reduces
total and LDL cholesterol in
overweight/obese patients
A, 1þ
Physical activity improves HDL
cholesterol levels
A, 1þ
Phytosterols daily use reduces total
and LDL cholesterol
A, 1þþ
Soy protein substitution for animal
protein reduces total and LDL
cholesterol
A, 1þ
Levels of evidence: 1þþ, high quality meta analyses, sys-
tematic reviews of RCTs, or RCTs with a very low risk of
bias; 1þ, well conducted meta analyses, systematic
reviews of RCTs, or RCTs with a low risk of bias. Grades
of recommendation: (A) At least one meta analysis,
systematic review, or RCT rated as 1þþ, and directly
applicable to the target population; or A systematic
review of RCTs or a body of evidence consisting princi-
pally of studies rated as 1þ, directly applicable to the
target population, and demonstrating overall consistency
of results. (B) A body of evidence including studies rated
as 2þþ, directly applicable to the target population,
and demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 1þþ
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